Can we ease the burden? study tests gentler drug dose for seniors after cancer transplant
Disease control
Recruiting now
This study aims to find the safest, most effective dose of an immune-suppressing drug (cyclophosphamide) for patients aged 65 and older who receive a stem cell transplant for blood cancers. Researchers want to see if a lower dose can still prevent complications from the transplan…
Phase: PHASE1 • Sponsor: Ronald Paquette • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC